SCHEDULE 13G/A: Major Investor TCG Crossover Reduces Stake in Dianthus Therapeutics Below 5%

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have amended their Schedule 13G filing, reporting a beneficial ownership of 4.7% in Dianthus Therapeutics, Inc., indicating a reduction in their stake.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G regarding their beneficial ownership in Dianthus Therapeutics, Inc.
• The Reporting Persons now collectively beneficially own 1,501,624 shares of Dianthus Therapeutics, Inc. Common Stock.
• This represents 4.7% of the Issuer's outstanding Common Stock, based on 32,125,179 shares reported in the Issuer's Form 10-K filed on March 11, 2025.
• The filing indicates that the Reporting Persons no longer hold more than 5% of the class, triggering this amendment.
• TCG Crossover GP II, LLC is the general partner of TCG Crossover II, and Chen Yu is the sole managing member of TCG Crossover GP II, with all three sharing voting and dispositive power over the reported shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant investor reducing their stake below the 5% reporting threshold, which can be interpreted as a loss of conviction or a strategic divestment, though no specific reason is provided.

Negatives

• The beneficial ownership of TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu in Dianthus Therapeutics, Inc. has decreased to 4.7%, falling below the 5% threshold that typically requires a Schedule 13G filing, indicating a reduction in their stake.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant institutional investor's position in a publicly traded biotechnology or pharmaceutical company (Dianthus Therapeutics, Inc. is implied to be in this sector given its name and typical issuer types for such filings). Such changes can be indicative of an investor's evolving strategy or outlook on the company or the broader sector, though the filing itself provides no specific reasons.

Stakeholder Impact

• Shareholders may perceive the reduction in stake by a significant institutional investor as a negative signal, potentially influencing stock price or investor confidence.

Key Dates

Keywords

Dianthus Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Shareholding, SEC Filing, Investment Fund